LAVA Therapeutics (LVTX) Stock Forecast, Price Target & Predictions
LVTX Stock Forecast
LAVA Therapeutics stock forecast is as follows: an average price target of $6.00 (represents a 482.52% upside from LVTX’s last price of $1.03) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.
LVTX Price Target
The average price target for LAVA Therapeutics (LVTX) is $6.00 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $6.00 to $6.00. This represents a potential 482.52% upside from LVTX's last price of $1.03.
LVTX Analyst Ratings
According to 3 Wall Street analysts, LAVA Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for LVTX stock is 0 'Strong Buy' (0.00%), 2 'Buy' (66.67%), 1 'Hold' (33.33%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
LAVA Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jun 28, 2024 | Arthur He | H.C. Wainwright | $6.00 | $1.88 | 219.15% | 482.52% |
| Mar 20, 2024 | Roger Song | Jefferies | $6.00 | $3.07 | 95.44% | 482.52% |
The latest LAVA Therapeutics stock forecast, released on Jun 28, 2024 by Arthur He from H.C. Wainwright, set a price target of $6.00, which represents a 219.15% increase from the stock price at the time of the forecast ($1.88), and a 482.52% increase from LVTX last price ($1.03).
LAVA Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 2 |
| Avg Price Target | - | - | $6.00 |
| Last Closing Price | $1.03 | $1.03 | $1.03 |
| Upside/Downside | -100.00% | -100.00% | 482.52% |
In the current month, the average price target of LAVA Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to LAVA Therapeutics's last price of $1.03. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Jun 28, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Sep 27, 2022 | SVB Leerink | Outperform | Outperform | Hold |
| Sep 16, 2022 | JMP Securities | Market Perform | Initialise |
LAVA Therapeutics's last stock rating was published by H.C. Wainwright on Jun 28, 2024. The company gave LVTX a "Buy" rating, the same as its previous rate.
LAVA Therapeutics Financial Forecast
LAVA Therapeutics Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Jun 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Sep 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | $2.64M | $15.26M | $468.00K | $1.00M | $1.78M | $921.00K |
| Avg Forecast | - | - | - | - | $1.52M | - | - | $2.17M | $22.91M | $573.05K | $232.32K | $255.97K | $777.17K | $567.37K | $322.64K | $9.26M |
| High Forecast | - | - | - | - | $1.52M | - | - | $2.17M | $22.91M | $573.05K | $232.32K | $255.97K | $777.17K | $567.37K | $322.64K | $11.11M |
| Low Forecast | - | - | - | - | $1.52M | - | - | $2.17M | $22.91M | $573.05K | $232.32K | $255.97K | $777.17K | $567.37K | $322.64K | $7.41M |
| # Analysts | - | - | - | - | 4 | - | - | 1 | 2 | 1 | 1 | 1 | 13 | 13 | 7 | 15 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | 11.36% | 59.62% | 0.60% | 1.76% | 5.52% | 0.10% |
LAVA Therapeutics's average Quarter revenue forecast for Jun 23 based on 1 analysts is $573.05K, with a low forecast of $573.05K, and a high forecast of $573.05K. LVTX's average Quarter revenue forecast represents a -78.29% decrease compared to the company's last Quarter revenue of $2.64M (Dec 22).
LAVA Therapeutics EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Jun 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Sep 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 4 | - | - | 1 | 2 | 1 | 1 | 1 | 13 | 13 | 7 | 15 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | $-4.19M | $-3.86M | $-10.72M | $-10.73M | $-7.13M | $-16.39M |
| Avg Forecast | - | - | - | - | $-913.78K | - | - | $-1.30M | $-13.75M | $-343.83K | $-139.39K | $-153.58K | $-466.30K | $-12.40M | $-193.58K | $-164.80M |
| High Forecast | - | - | - | - | $-913.78K | - | - | $-1.30M | $-13.75M | $-343.83K | $-139.39K | $-153.58K | $-466.30K | $-9.92M | $-193.58K | $-131.84M |
| Low Forecast | - | - | - | - | $-913.78K | - | - | $-1.30M | $-13.75M | $-343.83K | $-139.39K | $-153.58K | $-466.30K | $-14.87M | $-193.58K | $-197.76M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | 30.04% | 25.11% | 22.98% | 0.87% | 36.81% | 0.10% |
undefined analysts predict LVTX's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than LAVA Therapeutics's previous annual EBITDA (undefined) of $NaN.
LAVA Therapeutics Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Jun 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Sep 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 4 | - | - | 1 | 2 | 1 | 1 | 1 | 13 | 13 | 7 | 15 |
| Net Income | - | - | - | - | - | - | - | - | - | - | $-15.00M | $997.00K | $-7.92M | $-10.55M | $-7.46M | $-16.57M |
| Avg Forecast | $-7.48M | $-7.36M | $-7.48M | $-7.36M | $-8.26M | $-7.93M | $-8.33M | $-5.50M | $-10.73M | $-12.25M | $-15.66M | $-14.62M | $-21.46M | $-12.87M | $-54.36M | $-166.68M |
| High Forecast | $-7.48M | $-7.36M | $-7.48M | $-7.36M | $-7.70M | $-7.93M | $-8.33M | $-5.50M | $33.54M | $-12.25M | $-15.66M | $-14.62M | $-21.46M | $-10.30M | $-54.36M | $-133.35M |
| Low Forecast | $-7.48M | $-7.36M | $-7.48M | $-7.36M | $-8.82M | $-7.93M | $-8.33M | $-5.50M | $-55.01M | $-12.25M | $-15.66M | $-14.62M | $-21.46M | $-15.45M | $-54.36M | $-200.02M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | 0.96% | -0.07% | 0.37% | 0.82% | 0.14% | 0.10% |
LAVA Therapeutics's average Quarter net income forecast for Dec 22 is $-15.66M, with a range of $-15.66M to $-15.66M. LVTX's average Quarter net income forecast represents a -1670.77% decrease compared to the company's last Quarter net income of $997.00K (Sep 22).
LAVA Therapeutics SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Jun 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Sep 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 4 | - | - | 1 | 2 | 1 | 1 | 1 | 13 | 13 | 7 | 15 |
| SG&A | - | - | - | - | - | - | - | - | - | - | $3.71M | $3.10M | $3.02M | $4.30M | $3.21M | $1.42M |
| Avg Forecast | - | - | - | - | $2.00M | - | - | $2.86M | $30.15M | $754.19K | $305.75K | $336.88K | $1.02M | $746.71K | $424.62K | $12.19M |
| High Forecast | - | - | - | - | $2.00M | - | - | $2.86M | $30.15M | $754.19K | $305.75K | $336.88K | $1.02M | $746.71K | $424.62K | $14.63M |
| Low Forecast | - | - | - | - | $2.00M | - | - | $2.86M | $30.15M | $754.19K | $305.75K | $336.88K | $1.02M | $746.71K | $424.62K | $9.75M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | 12.15% | 9.19% | 2.95% | 5.76% | 7.57% | 0.12% |
LAVA Therapeutics's average Quarter SG&A projection for Jun 23 is $754.19K, based on 1 Wall Street analysts, with a range of $754.19K to $754.19K. The forecast indicates a -79.69% fall compared to LVTX last annual SG&A of $3.71M (Dec 22).
LAVA Therapeutics EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Jun 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Sep 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 4 | - | - | 1 | 2 | 1 | 1 | 1 | 13 | 13 | 7 | 15 |
| EPS | - | - | - | - | - | - | - | - | - | - | $-0.58 | $0.04 | $-0.31 | $-0.41 | $-0.29 | $-0.65 |
| Avg Forecast | $-0.28 | $-0.27 | $-0.28 | $-0.27 | $-0.31 | $-0.30 | $-0.31 | $-0.20 | $-0.40 | $-0.46 | $-0.58 | $-0.55 | $-0.80 | $-0.37 | $-2.03 | $-8.14 |
| High Forecast | $-0.28 | $-0.27 | $-0.28 | $-0.27 | $-0.29 | $-0.30 | $-0.31 | $-0.20 | $1.25 | $-0.46 | $-0.58 | $-0.55 | $-0.80 | $-0.37 | $-2.03 | $-6.52 |
| Low Forecast | $-0.28 | $-0.27 | $-0.28 | $-0.27 | $-0.33 | $-0.30 | $-0.31 | $-0.20 | $-2.05 | $-0.46 | $-0.58 | $-0.55 | $-0.80 | $-0.37 | $-2.03 | $-9.77 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | 0.99% | -0.07% | 0.39% | 1.12% | 0.14% | 0.08% |
According to 1 Wall Street analysts, LAVA Therapeutics's projected average Quarter EPS for Dec 22 is $-0.58, with a low estimate of $-0.58 and a high estimate of $-0.58. This represents a -1558.38% decrease compared to LVTX previous annual EPS of $0.04 (Sep 22).
LAVA Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| BNOX | Bionomics | $0.27 | $6.00 | 2122.22% | Buy |
| XLO | Xilio Therapeutics | $0.93 | $7.00 | 652.69% | Buy |
| TIL | Instil Bio | $21.69 | $150.00 | 591.56% | Hold |
| LVTX | LAVA Therapeutics | $1.04 | $6.00 | 476.92% | Buy |
| AVTE | Aerovate Therapeutics | $2.56 | $13.00 | 407.81% | Hold |
| CCCC | C4 Therapeutics | $4.05 | $20.00 | 393.83% | Buy |
| ANEB | Anebulo Pharmaceuticals | $1.31 | $6.00 | 358.02% | Buy |
| PMVP | PMV Pharmaceuticals | $1.52 | $6.00 | 294.74% | Buy |
| ANTX | AN2 Therapeutics | $1.34 | $5.00 | 273.13% | Buy |
| NXTC | NextCure | $0.90 | $3.00 | 233.33% | Buy |
| ACRV | Acrivon Therapeutics | $7.21 | $22.50 | 212.07% | Buy |
| ASMB | Assembly Biosciences | $14.28 | $35.50 | 148.60% | Buy |
| ADAG | Adagene | $2.10 | $5.00 | 138.10% | Buy |
| ERAS | Erasca | $2.63 | $6.00 | 128.14% | Buy |
| ACHL | Achilles Therapeutics | $0.97 | $2.00 | 106.19% | Buy |
| DSGN | Design Therapeutics | $6.25 | $9.67 | 54.72% | Buy |
| EWTX | Edgewise Therapeutics | $30.17 | $46.25 | 53.30% | Buy |
| RZLT | Rezolute | $4.44 | $6.67 | 50.23% | Buy |
| KRON | Kronos Bio | $0.96 | $1.00 | 4.17% | Buy |
| IKNA | Ikena Oncology | $1.62 | $1.33 | -17.90% | Buy |